Johnson & Johnson To Pay $2.2 Billion To Settle Deceptive Marketing Claims

Johnson & Johnson To Pay $2.2 Billion To Settle Deceptive Marketing Claims

For nearly a decade, various state and federal agencies have been looking into Johnson & Johnson’s marketing of the drugs Risperdal, Invega, Natrecor, and others, claiming the company was putting consumers at risk by paying kickbacks to doctors and pharmacists to suggest these drugs to patients and for pushing unapproved uses for these medications. Today, the Justice Dept. announced that J&J will pay out more than $2.2 billion to settle these claims. [More]